CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial...
Phase 2
Portland, Oregon, United States and 9 other locations
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune check ...
Phase 1, Phase 2
Portland, Oregon, United States and 20 other locations
fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by estimating the objective response rate ...
Phase 2
Portland, Oregon, United States and 10 other locations
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor...
Phase 1
Portland, Oregon, United States and 20 other locations
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have ...
Phase 2, Phase 3
Portland, Oregon, United States and 82 other locations
(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...
Phase 3
Tigard, Oregon, United States and 202 other locations
in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-re ...
Phase 1
Portland, Oregon, United States and 17 other locations
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors...
Phase 1, Phase 2
Portland, Oregon, United States and 39 other locations
in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSigna...
Phase 1, Phase 2
Portland, Oregon, United States and 66 other locations
CLDN6, in subjects with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., ...
Phase 1
Portland, Oregon, United States and 6 other locations
Clinical trials
Research sites
Resources
Legal